Data from The Clinical Respiratory Journal - Curated by EPG Health - Date available 01 September 2017

Original date published

1 September 2017

Original format

Epub ahead of print

BACKGROUND:

Despite using vasoactive and PH specific therapies, the in-hospital mortality of severe pulmonary hypertension (PH) with right heart failure (RHF) is high. We conducted a prospective analysis evaluating the efficacy and safety of levosimendan in PH patients with severe acute RHF.

METHODS:

Forty-five PH patients hospitalized between Jan 2016 to Nov 2016 were recruited into a single arm, prospective, open-label study. Levosimendan was administered at the rate of 0.05-0.1 μg/kg/min, up to a total dose of 12.5 mg. The primary endpoints were changes of World Health Organization Function Class (WHO-FC) and Borg dyspnoea scores. Secondary endpoints included changes in 6-min walk distance (6-MWD), biochemical markers and right heart structure and function together with adverse events on day 7, and incidence of major cardiovascular events (death or re-admission due to RHF) on day 30.

RESULTS:

Forty-five PH patients were enrolled. On the 7th day after levosimendan infusion, seven out of 13 PH patients with WHO-FC IV improved by one class (P = 0.008). Borg dyspnoea scores, 6-MWD and NT-proBNP improved significantly (P < 0.001). Compared with baseline, the right atrial transverse dimension, end-systolic eccentricity index and tricuspid annular plane systolic excursion improved significantly (58.8 ± 13.1 mm vs. 53.7 ± 12.4 mm; 1.50 ± 0.27 vs. 1.38 ± 0.23; 15.0 (13.0, 16.0) mm vs. 15.8 (14.0, 17.4) mm, P < 0.005, respectively). One patient occurred sudden death after discharge during follow-up.

CONCLUSIONS:

Intravenous levosimendan can effectively improve severe RHF of PH patients in hospital and well tolerated. This article is protected by copyright. All rights reserved.

Data sources

Read abstract on library site Access full article

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

+ 3 more

ESICM LIVES Highlights

ESICM LIVES Highlights

ESICM LIVES Congress 2018: Bringing you the latest news and insights from the 31st ESICM LIVES Congress, 20–24 October 2018 Paris, France.

Sleep Apnea

Sleep Apnea

Sleep apnea is a chronic condition characterised by recurrent interruptions in breathing throughout the sleep cycle. Learn about the two main types of sleep apnea and hear from experts as they present the latest research at the Sleep and Breathing conference (Marseille, 2019).

Load more

Related Content